Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

OPKO HEALTH, INC.

(OPK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Sector Update: Health Care Stocks Scratching Out Small Advance Just Ahead of Friday Close

07/30/2021 | 03:46pm EDT


ę MT Newswires 2021
All news about OPKO HEALTH, INC.
07:44aPFIZER : And opko announce extension of u.s. fda review of biologics license application o..
AQ
09/24PFIZER : OPKO Health Get FDA Extension for Review of Somatrogon Biologics License Applicat..
MT
09/24Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application ..
GL
09/14OPKO HEALTH : LeaderMed Form Joint Venture to Commercialize Two Drugs in Asia
MT
09/14OPKO HEALTH : LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercial..
AQ
09/14Leadermed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntom..
CI
09/13OPKO HEALTH : Another Diversity Suit Stifled
AQ
09/03OPKO HEALTH, INC. : Entry into a Material Definitive Agreement (form 8-K)
AQ
08/30OPKO HEALTH : Completes Phase 2 COVID-19 Study Enrollment at 171 Subjects
MT
08/30OPKO Health Completes Enrollment in Phase 2 Trial Evaluating RAYALDEE as a Treatment fo..
GL
More news
Analyst Recommendations on OPKO HEALTH, INC.
More recommendations
Financials (USD)
Sales 2021 1 595 M - -
Net income 2021 7,77 M - -
Net Debt 2021 - - -
P/E ratio 2021 313x
Yield 2021 -
Capitalization 2 554 M 2 554 M -
Capi. / Sales 2021 1,60x
Capi. / Sales 2022 2,16x
Nbr of Employees 5 269
Free-Float 59,5%
Chart OPKO HEALTH, INC.
Duration : Period :
OPKO Health, Inc. Technical Analysis Chart | OPK | US68375N1037 | MarketScreener
Technical analysis trends OPKO HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,75 $
Average target price 6,60 $
Spread / Average Target 76,0%
EPS Revisions
Managers and Directors
Phillip Frost Chairman & Chief Executive Officer
Jon Roger Cohen Director & Senior Vice President
Adam E. Logal CFO, Treasurer, Chief Accounting Officer & SVP
Jane H. Hsaio Vice Chairman & Chief Technical Officer
Steven D. Rubin Director & Executive Vice President-Administration
Sector and Competitors
1st jan.Capi. (M$)
OPKO HEALTH, INC.-5.06%2 554
JOHNSON & JOHNSON4.44%432 675
ROCHE HOLDING AG10.16%321 605
PFIZER, INC.19.37%246 358
NOVO NORDISK A/S50.45%231 485
ELI LILLY AND COMPANY37.22%210 037